| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
antiallergic activity (IC50 = 30 μM)
3',4'-Dihydroxyflavone targets inflammatory and allergic pathways. It exhibits antiallergic activity with an IC50 of 30 μM. The compound suppresses proinflammatory MAPK and NF-κB signaling pathways, contributing to its anti-inflammatory effects. It can also inhibit parasitophorous vacuole formation, modulate glial cell responses, and increase NO secretion. These activities suggest that 3',4'-dihydroxyflavone interacts with multiple targets involved in immune and inflammatory responses. |
|---|---|
| ln Vitro |
In vitro, 3',4'-dihydroxyflavone exhibits antiallergic activity with an IC50 value of 30 μM. It shows anti-inflammatory activity through suppression of the proinflammatory MAPK and NF-κB signaling pathways. The compound can inhibit parasitophorous vacuole formation, modulate glial cell responses, and increase NO secretion. These in vitro activities make 3',4'-dihydroxyflavone a valuable tool for studying allergic and inflammatory diseases, as well as neuroinflammation and cancer biology.
|
| ln Vivo |
In vivo activity of 3',4'-dihydroxyflavone has not been extensively reported. As a flavonoid with antiallergic and anti-inflammatory properties, it may have potential for treating allergic and inflammatory conditions in vivo. However, detailed in vivo efficacy data are limited in publicly available sources. The compound's potential applications include research on neuroinflammation, cancer biology, and amyloid pathology.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3',4'-dihydroxyflavone would typically involve screening against a panel of targets to identify its molecular interactions. Given its antiallergic activity, assays for histamine release inhibition, mast cell degranulation, or IgE-mediated responses would be appropriate. For anti-inflammatory activity, assays for COX-1/COX-2 inhibition, LOX inhibition, or NF-κB activity would be relevant. Binding to MAPK enzymes or other signaling proteins could be assessed using kinase activity assays or surface plasmon resonance.
|
| Cell Assay |
In vitro cell-based assays for 3',4'-dihydroxyflavone involve culturing appropriate cell lines (e.g., mast cells, macrophages, neuronal cells) and treating them with the compound to assess effects on allergic or inflammatory responses. For antiallergic activity, mast cells are sensitized with IgE and stimulated with antigen, and the release of histamine or other mediators is measured. For anti-inflammatory activity, macrophages are stimulated with LPS and cytokine production is measured. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for 3',4'-dihydroxyflavone would typically involve models of allergic or inflammatory disease. For type I allergy research, mice may be sensitized and challenged with an allergen, and the compound is administered to assess inhibition of allergic responses. For anti-inflammatory studies, models such as carrageenan-induced paw edema or LPS-induced systemic inflammation may be used. Dosing regimens and specific protocols vary depending on the research question. No standardized protocol is available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3',4'-dihydroxyflavone have not been extensively characterized. As a flavonoid, it is expected to have moderate oral bioavailability, with extensive metabolism by phase II enzymes (glucuronidation, sulfation) in the liver and intestine. Flavonoids are typically rapidly absorbed and eliminated, with a half-life of several hours. The compound's multiple hydroxyl groups contribute to its polarity and influence its distribution and excretion. No specific PK data are available.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3',4'-dihydroxyflavone has not been systematically evaluated. Flavonoids are generally considered to have low toxicity and are well-tolerated at moderate doses. However, high doses of certain flavonoids can cause cytotoxicity or genotoxicity. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
3',4'-Dihydroxyflavone is a synthetic flavonoid with antiallergic and anti-inflammatory activities. It has the molecular formula C15H10O4 and a molecular weight of 254.24. The compound exhibits antiallergic activity with an IC50 of 30 μM and suppresses proinflammatory MAPK and NF-κB signaling pathways. It is used for research on type I allergy, neuroinflammation, cancer biology, and amyloid pathology. 3',4'-Dihydroxyflavone is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C15H10O4
|
|---|---|
| Molecular Weight |
254.24
|
| Exact Mass |
254.058
|
| CAS # |
4143-64-0
|
| PubChem CID |
145726
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.443 g/cm3
|
| Boiling Point |
482.3ºC at 760 mmHg
|
| Melting Point |
251-253°C
|
| Flash Point |
188.4ºC
|
| Index of Refraction |
1.698
|
| LogP |
2.871
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2=C([H])C([H])=C([H])C([H])=C2C(C([H])=C1C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])=O
|
| InChi Key |
SRNPMQHYWVKBAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O4/c16-11-6-5-9(7-13(11)18)15-8-12(17)10-3-1-2-4-14(10)19-15/h1-8,16,18H
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (491.66 mM）
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
